[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ocugen Inc (OCGN)

Ocugen Inc (OCGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 467,160
  • Shares Outstanding, K 338,522
  • Annual Sales, $ 4,410 K
  • Annual Income, $ -67,850 K
  • EBIT $ -66 M
  • EBITDA $ -63 M
  • 60-Month Beta 2.30
  • Price/Sales 108.16
  • Price/Cash Flow N/A
  • Price/Book 82.22

Options Overview Details

View History
  • Implied Volatility 90.22% (-45.55%)
  • Historical Volatility 75.82%
  • IV Percentile 2%
  • IV Rank 2.32%
  • IV High 544.02% on 11/14/25
  • IV Low 79.44% on 05/20/26
  • Expected Move (DTE 17) 0.2295 (16.69%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 1,174
  • Volume Avg (30-Day) 1,986
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 79,835
  • Open Int (30-Day) 78,707
  • Expected Range 1.1455 to 1.6045

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.05
  • Number of Estimates 3
  • High Estimate $-0.04
  • Low Estimate $-0.06
  • Prior Year $-0.05
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2700 +7.09%
on 05/19/26
1.9000 -28.42%
on 05/04/26
-0.4400 (-24.44%)
since 05/01/26
3-Month
1.2700 +7.09%
on 05/19/26
2.7250 -50.09%
on 03/17/26
-0.4600 (-25.27%)
since 02/27/26
52-Week
0.8000 +70.00%
on 06/02/25
2.7250 -50.09%
on 03/17/26
+0.5239 (+62.66%)
since 05/30/25

Most Recent Stories

More News
Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes

MALVERN, Pa., May 14, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing...

OCGN : 1.3550 (-1.81%)
Ocugen to Participate in Upcoming May Scientific and Investor Conferences

MALVERN, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the...

OCGN : 1.3550 (-1.81%)
Ocugen: Q1 Earnings Snapshot

Ocugen: Q1 Earnings Snapshot

OCGN : 1.3550 (-1.81%)
Ocugen Provides Business Update with First Quarter 2026 Financial Results

Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p

OCGN : 1.3550 (-1.81%)
Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes

MALVERN, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen”) (NASDAQ: OCGN) today announced the pricing of $115 million aggregate principal amount of 6.75% Convertible Senior Notes due...

OCGN : 1.3550 (-1.81%)
Ocugen's Gene Therapy Timeline Finally Gets a Number Tomorrow

Barchart Research What to Expect from OCGN Earnings OCGN Generated May 4, 2026 Current Price $1.8500 EPS Estimate $$-0.05 Consensus Rating Strong Buy Average Move 6.53% Ocugen's Gene Therapy Timeline Finally...

OCGN : 1.3550 (-1.81%)
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes

MALVERN, Pa., May 04, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced...

OCGN : 1.3550 (-1.81%)
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results

MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...

OCGN : 1.3550 (-1.81%)
Ocugen to Present at April 2026 Investor and Industry Conferences

MALVERN, Pa., April 23, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that...

OCGN : 1.3550 (-1.81%)
Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of OCU410ST for Stargardt Disease

GARDian3 trial enrollment and dosing completed (N=63) in less than nine months Topline results expected in 2Q27 with BLA to follow by mid-2027 OCU410ST represents a potential first-in-class, one-time...

OCGN : 1.3550 (-1.81%)

Business Summary

Ocugen Inc. is a clinical stage biopharmaceutical company. It is focused on discovering, developing and commercializing therapies which address rare and underserved eye diseases. The company's product pipeline consists of OCU400, OCU300, OCU100 and OCU200 which are in clinical stage. Ocugen Inc., formerly...

See More

Key Turning Points

3rd Resistance Point 1.4517
2nd Resistance Point 1.4333
1st Resistance Point 1.4067
Last Price 1.3550
1st Support Level 1.3617
2nd Support Level 1.3433
3rd Support Level 1.3167

See More

52-Week High 2.7250
Fibonacci 61.8% 1.9896
Fibonacci 50% 1.7625
Fibonacci 38.2% 1.5353
Last Price 1.3550
52-Week Low 0.8000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.